Phenotypic Analysis of Splenocytes, Thymocytes, and Bone Marrow Cells in IFN-γ Transgenic Mice
| Tissue . | Phenotype . | Normal . | Transgenic . | ||
|---|---|---|---|---|---|
| . | . | % . | No. (×10−6) . | % . | No. (×10−6) . |
| Spleen | CD3+ | 54.6 ± 5.2 | 57.1 ± 10.3 | 92.4 ± 1.6* | 28.9 ± 3.0† |
| CD4+ (CD8−) | 42.7 ± 4.6 | 44.7 ± 9.9 | 71.7 ± 2.8* | 22.5 ± 2.9† | |
| CD8+ (CD4−) | 10.8 ± 1.8 | 11.1 ± 0.9 | 19.4 ± 1.2‡ | 6.1 ± 0.2* | |
| Mac-1+, GR1+ | 2.3 ± 0.7 | 2.4 ± 0.8 | 4.0 ± 1.1 | 1.2 ± 0.2 | |
| Mac-1+, GR1− | 2.1 ± 0.4 | 1.9 ± 0.2 | 0.7 ± 0.2‡ | 0.2 ± 0.0* | |
| TER119+ | 0.2 ± 0.0 | 0.2 ± 0.0 | 1.2 ± 5.8 | 0.2 ± 0.0 | |
| Thymus | CD4−, CD8− | 5.4 ± 0.7 | 4.7 ± 0.8 | 4.2 ± 5.8 | 4.7 ± 1.4 |
| CD4+, CD8+ | 68.6 ± 3.3 | 60.7 ± 10.1 | 55.0 ± 2.0‡ | 63.0 ± 10.6 | |
| CD4+, CD8− | 21.0 ± 2.4 | 18.5 ± 3.4 | 30.9 ± 1.1‡ | 35.3 ± 9.0† | |
| CD4−, CD8+ | 5.0 ± 0.2 | 4.4 ± 0.7 | 9.9 ± 0.9* | 11.2 ± 2.9† | |
| Bone marrow | CD3+ | 1.3 ± 0.2 | 0.4 ± 0.0 | 8.3 ± 1.1* | 1.3 ± 0.1* |
| CD4+ (CD8−) | 1.2 ± 0.1 | 0.3 ± 0.1 | 3.6 ± 0.4* | 0.6 ± 0.1† | |
| CD8+ (CD4−) | 0.3 ± 0.0 | 0.1 ± 0.0 | 2.9 ± 0.4‡ | 0.4 ± 0.0* | |
| Mac-1+, GR1+ | 44.7 ± 13.1 | 13.2 ± 4.2 | 69.2 ± 6.1† | 10.5 ± 1.2 | |
| Mac-1+, GR1− | 0.6 ± 0.2 | 0.6 ± 0.8 | 0.4 ± 0.3 | 0.1 ± 0.0 | |
| TER119+ | 23.6 ± 5.1 | 6.9 ± 1.5 | 22.4 ± 2.0 | 3.5 ± 1.1† | |
| Tissue . | Phenotype . | Normal . | Transgenic . | ||
|---|---|---|---|---|---|
| . | . | % . | No. (×10−6) . | % . | No. (×10−6) . |
| Spleen | CD3+ | 54.6 ± 5.2 | 57.1 ± 10.3 | 92.4 ± 1.6* | 28.9 ± 3.0† |
| CD4+ (CD8−) | 42.7 ± 4.6 | 44.7 ± 9.9 | 71.7 ± 2.8* | 22.5 ± 2.9† | |
| CD8+ (CD4−) | 10.8 ± 1.8 | 11.1 ± 0.9 | 19.4 ± 1.2‡ | 6.1 ± 0.2* | |
| Mac-1+, GR1+ | 2.3 ± 0.7 | 2.4 ± 0.8 | 4.0 ± 1.1 | 1.2 ± 0.2 | |
| Mac-1+, GR1− | 2.1 ± 0.4 | 1.9 ± 0.2 | 0.7 ± 0.2‡ | 0.2 ± 0.0* | |
| TER119+ | 0.2 ± 0.0 | 0.2 ± 0.0 | 1.2 ± 5.8 | 0.2 ± 0.0 | |
| Thymus | CD4−, CD8− | 5.4 ± 0.7 | 4.7 ± 0.8 | 4.2 ± 5.8 | 4.7 ± 1.4 |
| CD4+, CD8+ | 68.6 ± 3.3 | 60.7 ± 10.1 | 55.0 ± 2.0‡ | 63.0 ± 10.6 | |
| CD4+, CD8− | 21.0 ± 2.4 | 18.5 ± 3.4 | 30.9 ± 1.1‡ | 35.3 ± 9.0† | |
| CD4−, CD8+ | 5.0 ± 0.2 | 4.4 ± 0.7 | 9.9 ± 0.9* | 11.2 ± 2.9† | |
| Bone marrow | CD3+ | 1.3 ± 0.2 | 0.4 ± 0.0 | 8.3 ± 1.1* | 1.3 ± 0.1* |
| CD4+ (CD8−) | 1.2 ± 0.1 | 0.3 ± 0.1 | 3.6 ± 0.4* | 0.6 ± 0.1† | |
| CD8+ (CD4−) | 0.3 ± 0.0 | 0.1 ± 0.0 | 2.9 ± 0.4‡ | 0.4 ± 0.0* | |
| Mac-1+, GR1+ | 44.7 ± 13.1 | 13.2 ± 4.2 | 69.2 ± 6.1† | 10.5 ± 1.2 | |
| Mac-1+, GR1− | 0.6 ± 0.2 | 0.6 ± 0.8 | 0.4 ± 0.3 | 0.1 ± 0.0 | |
| TER119+ | 23.6 ± 5.1 | 6.9 ± 1.5 | 22.4 ± 2.0 | 3.5 ± 1.1† | |
Cells from the bone marrow, thymus, and spleen of 3-month-old FVB/NCr IFN-γ transgenic mice or littermate controls were examined for the percentage and number of cells contained within various phenotypic subsets using immunofluorescence labeling and FCA. The number of cells bearing a specific marker was calculated by multiplying the percentage of cells in a particular subset by the total number of cells in the tissue. The values are expressed as the mean ± SD of 3 mice/group. The total number of cells/tissue for normal littermate controls or transgenic mice, respectively, were as follows: bone marrow (1 femur and 1 tibia/mouse), 29.3 × 106 ± 1.0 × 106, 15.3 × 106 ± 2.8 × 106; thymus, 88.3 × 106 ± 13.4 × 106, 114.3 × 106 ± 31.4 × 106; and spleen, 104.3 × 106 ± 13.7 × 106, 31.3 × 106 ± 2.7 × 106.
Significantly different (P < .001) from normal littermate controls.
Significantly different (P < .05) from normal littermate controls.
Significantly different (P < .01) from normal littermate controls.